Alpha-9 Oncology’s Post

Good morning San Diego! Day two of #AACR24 … an overwhelming amount of interesting science, in the plenaries, posters and vendor booths. Some hot takes, which might be biased through my eyes… This year the buzziest categories of drugs are ADCs and KRAS agents. In my opinion, both are categories that will benefit dramatically from next generation Biomarkers to guide patient stratification, trial design and ultimately treatment decisions. If you agree, or, if you disagree, check out the Genialis poster tomorrow, presenting Genialis krasID, a first in class machine learning-driven predictive biomarker for response and benefit to KRAS inhibitors. www.genialis.com/krasID

The advancements of extracellular vesicles in immunotherapy: in their recent literature review, Nils Piernitzki and Oskar Staufer at the INM-Leibniz Institute for New Materials describe and explore the fundamental molecular mechanisms that underlie the unique functionality of EVs in conferring immunotherapeutic benefits. The authors also examine clinical trials in immunotherapy that have successfully utilised the distinctive molecular mechanisms of EVs https://lnkd.in/e3auf5A7 #extracellularvesicles #exosomes #immunotherapy #clinicaltrials #Vesiculab

#ICYMI In a recent Drug Development & Delivery article, our Distinguished Scientist and Strategic Leader, Art Levin, PhD, explores our efforts to develop a new class of RNA therapeutics called AOCs. A rapidly growing body of evidence reinforces the significant promise of AOCs to address many areas of unmet need in health in entirely new ways, starting with skeletal muscle diseases. At Avidity, we're harnessing our proprietary AOC platform to advance clinical programs targeting three rare muscle disorders: myotonic dystrophy type 1 (#DM1), Duchenne muscular dystrophy (#DMD), and facioscapulohumeral muscular dystrophy (#FSHD). Our early results with AOC technology highlight its ability to target diverse rare muscle disorders, positioning us as leaders in this cutting-edge field of innovation. Read the full article and learn about our recent milestones in all three programs: https://lnkd.in/eq-MCCVf

A reliable and commercially scalable supply of the therapeutic radioisotope, Cu-67, is a critical component of Clarity’s success in developing life changing treatments for children and adults living with cancer. This is why we have partnered with NorthStar Medical Radioisotopes, LLC, a leader in the manufacturing of therapeutic radioisotopes, such as Cu-67, who are routinely producing high activity, high specific activity and high purity Cu-67 for use in Clarity’s ongoing clinical programs. Watch the video below for an exciting ‘behind the scenes’ look into the process and team that produce Cu-67 for use with Clarity’s Targeted Copper Theranostics. #Cu67 #Radiopharmaceutials #Theranostics

What is a B cell, and what is the significance of B-cell repertoire profiling?    At Cerba Research, B cells have the potential to help us develop personalized therapies and diagnostics for a future of precision and predictive medicine.   In our latest white paper, we examine B cells and their potential, explain how B cell repertoire is generated, and highlight their key benefits for clinical trials, from enabling high-throughput discovery capabilities to antibody selection and longitudinal patient monitoring in clinical trials.   We also introduce you to the BCR sequencing workflow used here at Cerba Research, and discuss its features and benefits.   You can read the full white paper here: https://lnkd.in/dZHYzFfr

In our latest interview sponsored by Sartorius, Maryna Panamarova, a Cellular Modelling Technical Specialist at the Wellcome Sanger Institute (Cambridge, UK) discusses the emergence of tumor organoids, tips for best practice when using them and the impact that they are having on the drug development field. Read now >>> https://hubs.ly/Q02wPQGp0

Comparing activation methods to yield clinical-scale expansion of γδ #Tcells Some #Tcelltherapies have been approved to treat patients with conditions like #Bcellmalignancies and #multiplemyeloma, but their use for #solidtumors remains challenging. Gamma delta (γδ) T cells have the inherent ability to infiltrate solid tumors and kill transformed cells, but their low prevalence in peripheral blood poses a challenge when generating enough cells to produce a clinical dose. Next month, Lonza Bioscience Solutions’ Chengkang Zhang (Associate Director, R&D) will present two novel methods for the expansion of #gammadeltaTcells from peripheral blood #mononuclearcells (PBMCs) and present data showcasing their suitability for clinical applications Register for this upcoming #webinar below:

Thanks to Medical Laboratory Observer for sharing our decision impact study news! 🔬 Choosing the right therapy for metastatic #NSCLC is complex, with new #biomarkers continuing to evolve in clinical practice. Our study demonstrates how the PROphetNSCLC test, a plasma #proteomics machine learning-based assay, can significantly impact oncologists' treatment choices, especially when combined with PD-L1 expression. Read more: https://lnkd.in/dJfXvfh6

🔬 Insights from ASCO 2024! Prof Mariana Brandao from Institut Jules Bordet presents the latest ctDNA analysis from the ADAURA trial on adjuvant osimertinib in resected stage I-III NSCLC. The study suggests that ctDNA monitoring could help tailor treatment duration, potentially reducing toxicity and improving patient quality of life. Discover the implications for clinical practice. Discover these updates.👇 For all ASCO 2024 videos, find the link in the comments! #MediMix #ASCO2024 #LungCancer #OncologyInnovation #ADAURATrial #ctDNA